Home » Bristol Meyer Squibb changes strategy and launches 16 new drugs on the market

Bristol Meyer Squibb changes strategy and launches 16 new drugs on the market

by admin
Bristol Meyer Squibb changes strategy and launches 16 new drugs on the market

Brystol Meyer Squibb, a moment of change and 360 degree recovery

The American company, one of the Big Pharmas, founded in 1887 and based in New York is experiencing a moment of mutation, immersed in a transformation plan to become one of the large growing pharmaceutical companies, a biopharmaceutical company that develops drugs all over the world. cutting edge by accelerating innovation.

Although it will face obstacles, such as regulation of drug prices in the United States, a more competitive environment and the loss of patents during this decade (impact on revenues) the direction is decided. In this sense the new CEO, Christopher Boerner, intends to change the product portfolio from top to bottom. “We don’t look for molecules that are copies or very similar to others. We are going to areas where there may be less prevalence, but we want to be the first to arrive with new mechanisms of action for those diseases where therapeutic solutions do not yet exist or are few”.

Brystol Meyers Squibb, the role of Europe

In this strategy Europe (led by Spain) plays an important role. In particular, Spain has the largest number of clinical trials outside the United States (112 clinical trials). Yet the only early-stage molecule research and development center outside of North America, it is in Seville. This translational research center applies advanced computing and artificial intelligence to discover biomarkers, therapeutic targets and new molecules.

The new strategy has two legs, on the one hand the development of new drugs, on the other the purchase of new companies to compensate for the deficits caused by drugs such as Revlimid. Among these acquisitions it is worth mentioning Mirati Therapeutics, (oncology and immunotherapy), RayzeBio (nuclear oncology) and Karuna (neurodegenerative diseases). Major investments in the order of $24 billion made possible by solid earnings. The numbers achieved are significant: 45,000 million dollars in 2023, slightly lower than those of 2022 due to the decline in sales of the anti-cancer drug Revlimid, but with a growth of 7% if new products are considered.

See also  Covid Pfizer vaccine: more than 90 percent efficacy in children

And always related to the new strategy, which focuses on oncology and hematology, Collaborations with other pharmaceutical companies are planned such as the one with Pfizer for thrombosis, or the one with SystImmune. And there is no shortage of new products on the launch pad (16). These include Opdualag against lung cancer, Sotyktu, the first oral daily therapy against psoriasis and Abecma, a CAR-T cell therapy against myeloma. Is the future all pink for BMS? Perhaps yes, although Morgan Stanley analysts seem to be more cautious as they believe that new drugs will not compensate for the lower sales of “old” drugs due to competition from generics. In any case, only time will confirm the correctness of the new direction of the Pharma giant.

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy